This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
1. The Bristol Myers Squibb (BMS)/Celgene GSPT1 degrader (CC-90009) is a CRBN-based molecular glue (CELMoD). It is a clinical candidate…
molecule
2 years ago ●
1 min read
2. The Novartis LTA4H metalloenzyme inhibitor, LYS006, is a selective oral agent in multiple Ph. II studies to treat inflammatory…
molecule
2 years ago ●
1 min read
3. The Eisai STING agonist E7766 leads to tumor eradication in 9/10 treated animals in a syngeneic model when injected…
molecule
2 years ago ●
1 min read
4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small…
molecule
2 years ago ●
1 min read
5. The Millenium/Takeda SUMO-activating enzyme (SAE) inhibitor TAK-981 is a mechanism-based inhibitor that covalently forms a SUMO substrate-inhibitor adduct that…
molecule
2 years ago ●
1 min read
6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy,…
molecule
2 years ago ●
1 min read
Load More
